Souhaitez-vous accéder aux communiqués récents ?

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to enroll 250 patients to receive treatment over 36 weeks...

New Canadian guideline for pediatric obesity care shifts focus from weight loss to improving health, mental wellbeing, and quality of life.

New Canadian guideline for pediatric obesity care shifts focus from weight loss to improving health, mental wellbeing, and quality of life.

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo...

Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering. Across the 68 markets, sales in the...

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter...

Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the...